SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microvast Holdings, Inc. is an advanced battery technology company. It engages in the business of designing, developing, and manufacturing battery components and systems primarily for electric commercial vehicles and utility-scale energy storage systems. The company was founded by Yang Wu on October 12, 2006 and is headquartered in Stafford, TX.

Microvast Holdings Inc

Microvast ($MVST) is surging, with the community focused on its potential for a short squeeze and its progress in EU revenues. Many believe $MVST is undervalued compared to peers and anticipate a significant move upwards, fueled by positive technical indicators and upcoming earnings. The community is actively discussing its small float, low short interest, and potential for further growth.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

OMER is trending amid renewed community excitement, with many expressing anticipation for a potential short squeeze and significant upward movement. Discussions are focused on a recent deal with Novo Nordisk, with some speculating about the potential for additional news and a potential impact on the company's market capitalization. The community seems bullish, viewing OMER as undervalued in the biotech sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp is trending as the community discusses a significant price swing and potential short squeeze, with some attributing the volatility to broader sector movements and others pointing to company-specific catalysts. Bullish sentiment revolves around the company's position as a domestic antimony producer amid increasing geopolitical tensions related to rare earth mineral supply. Many are speculating about potential government support and long-term growth prospects.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling, with some community members pointing to a video from a senior advisor to President Trump as a catalyst. A trading halt and subsequent price movement in cannabis stocks have intensified the buzz, as investors discuss potential catalysts like Veterans Day. Community members are actively debating the timing and impact of any policy changes.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ ($LAES) is trending amid discussions around a recent offering and its potential impact on the stock. While some community members express concern over dilution, others view it as a strategic move to fuel growth in the quantum computing sector, pointing to upcoming catalysts and strong backing from institutional investors. The stock's recent gains and high trading volume are also fueling the conversation.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid escalating U.S.-China trade tensions and China's export restrictions on rare earth materials, vital for tech and defense, which are driving interest in Western producers. Community members are actively discussing potential price targets, loading up on dips, and anticipating further upside due to the increasing strategic importance of rare earth elements. Some investors believe the stock is overvalued, while others suggest the company is still undervalued, anticipating government action.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

ROOT is trending as investors discuss potential catalysts, including partnerships and upcoming earnings, with a focus on PIF growth. Community members are debating the company's long-term potential against its current valuation, profitability, and the CEO's performance. Some traders are noting technical indicators and potential short squeezes, while others express concern over management and recent price action compared to peers.

Sadot Group, Inc. operates as a restaurant chain business. It operates through the following segments: Muscle Maker Grill Restaurant, Pokemoto Hawaiian Poke Restaurant, Non-Traditional (Hybrid), SuperFit Foods Meal Prep, and Sadot. The firm offers protein- based meals featuring chicken, seafood, pasta, hamburgers, wraps and flat breads. It also provides salads, protein shakes and fruit smoothies. The company was founded by Rodney C. Silva in 2022 and is headquartered in Burleson, TX.

Sadot Group Inc

SDOT is trending as community members discuss its potential due to a low float and news regarding possible trade measures impacting cooking oil. Some traders are pointing to the company's potential to move into crypto, while others highlight strong revenue despite past dilution concerns. Overall, the stock sees speculative interest driven by macro events and sector momentum.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as community members discuss its potential breakout and recent partnership with OpenAI, with many eyeing call options. Some traders express concerns about valuation and overbought conditions, while others point to strong international sales and AI integration as growth drivers. Overall sentiment appears mixed, with a focus on short-term trading opportunities.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to positive earnings reports and increased revenue guidance, with the community highlighting the blockbuster potential of Recorlev and XP-8121. Investors are optimistic about the company's path to profitability and are discussing potential buyout scenarios. Bullish sentiment is fueled by growing institutional ownership and expectations of continued growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Azenta Announces the Election of Dipal Doshi to its Board of Directors Azenta Announces the Election of Dipal Doshi to its Board of Directors PR Newswire BURLINGTON, Mass., Jan. 30, 2025 BURLINGTON...

The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.

The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. The United Mitochondrial Disease...

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on TRDA stock, giving a Buy rating on March 13. Ram Selvaraju has given h...

Equities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA  Free Report)  Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research...

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

Extended Cash Runway and Progress in Duchenne Muscular Dystrophy Treatments Mark 2023 MilestonesRelated Stocks: TRDA...

Entrada Therapeutics expects cash to fund requirements through 2Q26

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Entrada Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$6.25
Prev Close	$6.06
Open	$6.17
Dividend Yield	0.00%
50-Day Moving Average	$5.55
Beta	1.16
Avg. Volume	394,146.95
PE Ratio	-3.40

52-Week High	$21.79
52-Week Low	$4.93
Market Capitalization	$230.5M
EPS (Annual)	$1.68
Price to Book	0.61
Revenue Per Employee	$1.15M
Enterprise Value/EBITDA	N/A

TRDA
Entrada Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRDA News

TRDAEntrada Therapeutics Inc